EP2167026B1 - Cosmetic composition for treatment of canities - Google Patents
Cosmetic composition for treatment of canities Download PDFInfo
- Publication number
- EP2167026B1 EP2167026B1 EP08760661.2A EP08760661A EP2167026B1 EP 2167026 B1 EP2167026 B1 EP 2167026B1 EP 08760661 A EP08760661 A EP 08760661A EP 2167026 B1 EP2167026 B1 EP 2167026B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- khellin
- hair
- canities
- use according
- mask
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Definitions
- the present invention concerns the topical use of Khellin to reduce the amount of grey and white hair due to canities.
- Khellin, or 4,9-dimethoxy-7-methyl-5H-furo[3,2-g][1]benzopyran-5-one is a derivative of coumarin which is known for its vasodilatory properties.
- EP680761 (Indena ) relates to topical formulations based on khellin for cicatrizing the skin by means of its peripheral vasokinetic activity.
- EP693278 (Indena ) relates to formulations against hair loss based on khellin, combined with unsaturated fatty acids, again utilizing its peripheral vasokinetic activity.
- Khellin has also been studied for therapy of the skin disorder known as vitiligo, characterized by non-pigmented skin patches.
- NB narrow band
- UVB ultraviolet rays
- khellin for topical use is effective in reducing the amount of white hair due to canities without having to combine it with other agents such as UV light.
- the current invention presents a composition for cosmetic use able to reduce the amount of white hair due to canities, characterized by comprising khellin as the active principle and excipients that render it suitable for topical use on hair.
- khellin can be present as the only active principle in the composition or in combination with one or more additional active principles, chosen from phenylalanine, ornithine, catechin, quercetin, copper salts such as copper gluconate.
- composition of the invention can be prepared in the form of a possibly liposomal hair treatment mask, or shampoo, or lotion, or conditioner, or mousse.
- khellin is comprised in a quantity between 0.2 and 1.8% w/v.
- the quantity of each of the components is expressed as percentage weight per volume, % w/v, or, in the case of lotions, as weight in grams per 100 ml.
- Example 1 Liposomal hair mask
- INGREDIENTS (INCI names) g in 100 ml 1 Citric acid 0.04-0.052 2 Disodium EDTA 0.03-0.06 3 Alcohol 15-20 4 PEG-40 Hydrogenated castor oil 0.5-3 5 Tween 20 0.5-1.0 6 Per10 7 Khellin 0.5-1.8 8 Water q.s. to 100 ml
- Example 5 Specific shampoo for problems of the scalp
- INGREDIENTS (INCI names) % w/v 1 Disodium EDTA 0.10-0.30 2 Polyquaternium-10 0.10-0.30 3 Polyquaternium-55 0.1-0.50 4 Citric acid 0.60-0.80 5 Potassium undecylenoyl hydrolyzed wheat protein 3.6000 6 Sodium lauroyl sarcosinate 1.5000 7 Cocamide mipa 1.0-3.0 8 Disodium laureth sulfosuccinate 1.0-5.0 9 Disodium capryloyl glutamate 0.4-1.0 10 Zinc coceth sulfate 1.0-8.0 11 PEG-200 hydrogenated glyceryl palmate 0.5-3.0 12 PEG-7 glyceryl cocoate 0.5-2.0 13 Laureth-2 0.05-2.0 14 PEG-40 hydrogenated castor oil 0.2-1.0 15 perfume q.s. 16 Phenyl trimethicone 0.05-3.0 17 Silicone quaternium-15 0.005-1.0 18 Laureth-4
- Example 7 Liposomal mask for hair
- INGREDIENTS (INCI names) g in 100 ml 1 Citric acid 0.04-0.052 2 Disodium EDTA 0.03-0.06 3 Alcohol 15-20 4 PEG-40 Hydrogenated castor oil 0.5-3 5 Tween 20 0.5-1.0 6 perfume 0.10 7 Khellin 0.5-1.8 8 Ornithine 0.2-0.5 Water q.s. to 100 ml
- Example 11 Specific shampoo for problems of the scalp
- INGREDIENTS (INCI names) % w/v 1 Disodium EDTA 0.10-0.30 2 Polyquaternium-10 0.10-0.30 3 Polyquaternium-55 0.1-0.50 4 Citric acid 0.60-0.80 5 Ornithine 0.10-0.05 6 Potassium undecylenoyl hydrolyzed wheat protein 3.6000 7 Sodium lauroyl sarcosinate 1.5000 8 Cocamide mipa 1.0-3.0 9 Phenylalanine 0.10-0.50 10 Disodium laureth sulfosuccinate 1.0-5.0 11 Disodium capryloyl glutamate 0.4-1.0 12 Zinc coceth sulfate 1.0-8.0 13 Peg-200 hydrogenated glyceryl palmate 0.5-3.0 14 Peg-7 glyceryl cocoate 0.5-2.0 15 Laureth-2 0.05-2.0 16 Peg-40 hydrogenated castor oil 0.2-1.0 17 perfume q.s.
- a double-blind clinical study was carried out using a mask 1-A in accordance with the invention comprising 1.5% w/v khellin in combination with phenylalanine, ornithine, copper gluconate and excipients suitable for topical application to hair, compared with the use of a placebo formulation 1-B, i.e. a similar mask base for hair but without the active principle.
- the subjects in active group A used a gentle shampoo 2-A containing 1% khellin and formulated with liposomes, to be used twice weekly for four weeks.
- non-active group B used a normal gentle shampoo 2-B as a comparison, i.e. without active principles.
- shampoo 2-A was shown to be effective in maintaining the action of mask 1-A treatment.
- composition of the invention is mainly indicated for anti-ageing cosmetic use, for preventing and treating canities and hence ageing of the hair.
- composition of the invention Following topical application of the composition of the invention to hair, an increase in the anagen phase of the hair growth cycle (compared to the baseline) as well as an increase in hair shaft diameter in subjects affected by androgenetic alopecia was generally also apparent.
- composition of the invention is particularly indicated for the treatment of canities associated with androgenetic alopecia.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Description
- The present invention concerns the topical use of Khellin to reduce the amount of grey and white hair due to canities.
- Khellin, or 4,9-dimethoxy-7-methyl-5H-furo[3,2-g][1]benzopyran-5-one is a derivative of coumarin which is known for its vasodilatory properties.
-
US4412071 (UpJohn ) describes khellin analogues indicated as anti-arteriosclerosis agents. -
EP680761 (Indena -
EP693278 (Indena - Khellin has also been studied for therapy of the skin disorder known as vitiligo, characterized by non-pigmented skin patches. In this regard, research has shown how the use of NB (narrow band) UVB is particularly effective in the treatment of said disease. Procaccini (Ann. Ital. Dermatol. Clin. Sper., 1993, 47, 4) reports that applying khellin topically would not in itself have a specific repigmentation action against vitiligo, any effective repigmentation action being essentially due to induction by UV rays.
- According to the present invention, it has been surprisingly found that khellin for topical use is effective in reducing the amount of white hair due to canities without having to combine it with other agents such as UV light.
- Principally to achieve this activity but also other advantages which will be described henceforth, the current invention presents a composition for cosmetic use able to reduce the amount of white hair due to canities, characterized by comprising khellin as the active principle and excipients that render it suitable for topical use on hair.
- According to the present invention, khellin can be present as the only active principle in the composition or in combination with one or more additional active principles, chosen from phenylalanine, ornithine, catechin, quercetin, copper salts such as copper gluconate.
- The composition of the invention can be prepared in the form of a possibly liposomal hair treatment mask, or shampoo, or lotion, or conditioner, or mousse. Preferably, in a composition according to the invention khellin is comprised in a quantity between 0.2 and 1.8% w/v. With the aim of better understanding the characteristics of the invention, nonlimiting examples of its practical implementation are described in the following.
- The quantity of each of the components is expressed as percentage weight per volume, % w/v, or, in the case of lotions, as weight in grams per 100 ml.
- In the examples, where indicated, the INCI names of the components are given in accordance with the International Nomenclature of Cosmetic Ingredients.
-
Components % w/v 1 Glycerin 3.00 5 Tween 20 1.00 6 Cremophor 0.30 7 Aristoflex 0.70 8 Phenonip 0.98 9 Copper gluconate 0.10 11 Cromollient SCE 3.00 13 Cremophor 0.60 14 Khellin 1.0-1.5 15 Phosal 75 SA 3.00 16 Parfum 0.60 17 Patent blue (0.2% solution) 0.30 18 Demineralized water q.s. to 100 ml -
Components % w/v 1 Corn starch 1.5 2 BC 2366 2.5 3 Disodium EDTA 0.2 4 Cetrimonium chloride 4 5 Salcare SC 92 2 6 Glycerin 4 7 Nexbase 2004 2 8 Fancol VB 1.5 9 BC 2262 0.5 10 Lanette O 1.5 11 Palm oil 0.8 12 Brij 721 1 13 Khellin 0.5-1.5 14 Crodazosoft DBQ 8 15 Cremophor RH 40 0.2 16 Tween 20 0.9 17 Glycerin 3.0 18 Incroquat behenyl tms 0.5-0.7 19 Cromollient SCE 0.6 20 Tween 20 0.1 21 Parfum 0.5 22 Phenonip 1 23 Water q.s. to 100 ml -
Components % w/v 1 EDTA 0.20 2 Polyquaternium-10 0.40 3 Sodium Lauroyl Sarcosinate 9.00 4 Magnesium laureth sulfate (75%) and Disodium laureth sulfosuccinate (25%) 38.00 5 Potassium Undecylenoyl Hydrolyzed wheat protein 1.00 6 PEG-40 Hydrogenated Castor Oil 0.50 7 Polysorbate 20 1.00 8 Cremophor RH 40 0.2 9 Tween 20 0.9 10 Glycerin 3.0 11 cromollient SCE 0.6 12 Prolipid 151 0.6 13 khellin 0.5-1.5 14 tween 20 0.3 15 cremophor RH40 6 16 Phenyltrimethicone & Silicone Quaternium-15 0.50 17 Silicone quaternium-15 & C11-15 Pareth-5 & C11-15 Pareth-9 0.80 18 Parfum 12144 0.60 19 BHA 0.01 20 Crodasilk liquid 1.00 21 Lauryl Methyl Gluceth-10 Hydroxypropyldimonium Chloride 0.50 22 Wheat (triticum vulgare) gliadins 1.00 23 Dore Gold AS232 0.05 24 Glycol Distearate, Laureth-7, Sodium Cocoamphoacetate, Cocamidopropyl Betaine and Sodium Laureth Sulfate 6.00 25 PEG-90 Glyceryl Isostearate (and) Laureth-2 1.20 26 PEG-120 Methyl Glucose dioleate 1.20 27 KCl 0.60 28 phenoxyethanol, methylparaben, butylparaben, ethylparaben, propylparaben 0.98 29 citric acid 0.50 30 Demineralized water q.s. to 100.00 -
INGREDIENTS (INCI names) g in 100 ml 1 Citric acid 0.04-0.052 2 Disodium EDTA 0.03-0.06 3 Alcohol 15-20 4 PEG-40 Hydrogenated castor oil 0.5-3 5 Tween 20 0.5-1.0 6 Parfum 0.10 7 Khellin 0.5-1.8 8 Water q.s. to 100 ml -
INGREDIENTS (INCI names) % w/v 1 Disodium EDTA 0.10-0.30 2 Polyquaternium-10 0.10-0.30 3 Polyquaternium-55 0.1-0.50 4 Citric acid 0.60-0.80 5 Potassium undecylenoyl hydrolyzed wheat protein 3.6000 6 Sodium lauroyl sarcosinate 1.5000 7 Cocamide mipa 1.0-3.0 8 Disodium laureth sulfosuccinate 1.0-5.0 9 Disodium capryloyl glutamate 0.4-1.0 10 Zinc coceth sulfate 1.0-8.0 11 PEG-200 hydrogenated glyceryl palmate 0.5-3.0 12 PEG-7 glyceryl cocoate 0.5-2.0 13 Laureth-2 0.05-2.0 14 PEG-40 hydrogenated castor oil 0.2-1.0 15 Parfum q.s. 16 Phenyl trimethicone 0.05-3.0 17 Silicone quaternium-15 0.005-1.0 18 Laureth-4 0.010-0.5 19 Khellin 0.5-1.8 20 Water q.s. to 100 ml -
Ingredients (INCI names) % w/v 1 Alcohol denat. 12.0-15.0 4 Ethoxydiglycol 1.0-3.0 5 Sodium lauryl sulfate 0.5-2.0 6 Sodium hydroxide 0.01-0.06 7 Citric acid 0.01-0.06 8 Peg-40 hydrogenated castor oil 0.30-0.60 9 Parfum q.s 10 Tocotrienols 0.01-0.05 11 Potassium undecylenoyl hydrolyzed wheat protein 0.050-1.0 12 Zinc coceth sulfate 0.050-0.1 13 Polyquaternium-16 0.020 14 Khellin 0.2-0.5 15 Water q.s. to 100ml -
Components % w/v 1 Glycerin 3.00 Ornithine 0.20-0.9 3 Phenylalanine 0.20-0.60 4 Pycnogenol 0.10-0.50 5 Tween 20 1.00 6 Cremophor 0.30 7 Aristoflex 0.70 8 Phenonip 0.98 9 Copper gluconate 0.10 10 Catechin 0.05-0.1 11 Cromollient SCE 3.00 12 Quercetin 0.01-0.1 13 Cremophor 0.60 14 Khellin 0.3-1.3 15 Phosal 75 SA 3.00 16 Parfum 0.60 17 Patent blue (0.2% solution) 0.30 18 Demineralized water q.s. to 100 ml -
Components % w/v 1 Corn starch 1.5 2 Ornithine 0.8-1.20 3 Phenylalanine 0.1-0.40 4 Copper gluconate 0.05-0.1 5 BC 2366 2.5 6 Disodium EDTA 0.2 7 Cetrimonium chloride 4 8 Salcare SC 92 2 9 Glycerin 4 10 Nexbase 2004 2 11 Ceramide A2 0.2-0.5 12 Fancol VB 1.5 13 BC 2262 0.5 14 Lanette O 1.5 15 Palm Oil 0.8 16 Brij 721 1 17 Khellin 0.5-1.5 18 Crodazosoft DBQ 8 19 Catechin 0.025-0.07 20 Cremophor RH 40 0.2 21 Tween 20 0.9 22 Glycerin 3.0 23 Panthenol 0.1-0.25 24 Nanocream 0.8-1.2 25 Incroquat behenyl tms 0.5-0.7 26 Quercetin 0.01-0.005 27 Cromollient SCE 0.6 28 Tween 20 0.1 29 Parfum 0.5 30 Phenonip 1 31 Water q.s. to 100 ml -
Components % w/v 1 EDTA 0.20 2 Ornithine 0.5-1.2 3 Phenylalanine 0.2-0.6 4 Copper gluconate 0.08-0.12 5 Polyquaternium-10 0.40 6 Sodium Lauroyl Sarcosinate 9.00 7 Magnesium laureth sulfate (75%) and Disodium laureth sulfosuccinate (25%) 38.00 8 Potassium Undecylenoyl Hydrolyzed wheat protein 1.00 9 PEG40 Hydrogenated Castor Oil 0.50 10 Polysorbate 20 1.00 11 Catechin 0.025-0.07 12 Pycnogenol 0.05-0.15 13 Cremophor RH 40 0.2 14 Tween 20 0.9 15 glycerin 3.0 16 panthenol 0.2 17 nanocream 10 18 Quercetin 0.01-0.005 19 cromollient SCE 0.6 20 Prolipid 151 0.6 21 khellin 0.5-1.5 22 tween 20 0.3 23 cremophor RH40 6 24 Phenyltrimethicone & Silicone Quaternium-15 0.50 25 Silicone quaternium-15 & C11-15 Pareth-5 & C11-15 Pareth-9 0.80 26 Parfum 12144 0.60 27 BHA 0.01 28 Crodasilk liquid 1.00 29 Lauryl Methyl Gluceth-10 Hydroxypropyldimonium Chloride 0.50 30 Wheat (triticum vulgare) gliadins 1.00 31 Hairspheres Biogenina 0.2-0.3 32 Dore Gold AS 232 0.05 33 Glycol Distearate, Laureth-7, Sodium Cocoamphoacetate, Cocamidopropyl Betaine and Sodium Laureth Sulfate 6.00 34 PEG-90 Glyceryl Isostearate (and) Laureth-2 1.20 35 PEG-120 Methyl Glucose dioleate 1.20 36 KCI 0.60 37 phenoxyethanol, methylparaben, butylparaben, ethylparaben, propylparaben 0.98 38 citric acid 0.50 39 Demineralized water q.s. to 100.00 ml -
INGREDIENTS (INCI names) g in 100 ml 1 Citric acid 0.04-0.052 2 Disodium EDTA 0.03-0.06 3 Alcohol 15-20 4 PEG-40 Hydrogenated castor oil 0.5-3 5 Tween 20 0.5-1.0 6 Parfum 0.10 7 Khellin 0.5-1.8 8 Ornithine 0.2-0.5 Water q.s. to 100 ml -
INGREDIENTS (INCI names) % w/v 1 Disodium EDTA 0.10-0.30 2 Polyquaternium-10 0.10-0.30 3 Polyquaternium-55 0.1-0.50 4 Citric acid 0.60-0.80 5 Ornithine 0.10-0.05 6 Potassium undecylenoyl hydrolyzed wheat protein 3.6000 7 Sodium lauroyl sarcosinate 1.5000 8 Cocamide mipa 1.0-3.0 9 Phenylalanine 0.10-0.50 10 Disodium laureth sulfosuccinate 1.0-5.0 11 Disodium capryloyl glutamate 0.4-1.0 12 Zinc coceth sulfate 1.0-8.0 13 Peg-200 hydrogenated glyceryl palmate 0.5-3.0 14 Peg-7 glyceryl cocoate 0.5-2.0 15 Laureth-2 0.05-2.0 16 Peg-40 hydrogenated castor oil 0.2-1.0 17 Parfum q.s. 18 Phenyl trimethicone 0.05-3.0 19 Silicone quaternium-15 0.005-1.0 20 Laureth-4 0.010-0.5 21 Khellin 0.5-1.8 22 Catechin 0.025-0.07 23 Quercetin 0.01-0.005 24 Water q.s. to 100 ml -
Ingredients (INCI names) % w/v 1 Alcohol denat. 12.0-15.0 2 Ornithine 0.050-0.20 3 Salicylic acid 0.05-0.02 4 Ethoxydiglycol 1.0-3.0 6 Sodium lauryl sulfate 0.5-2.0 7 Sodium hydroxide 0.01-0.06 8 Citric acid 0.01-0.06 9 Panthenol 0.200 10 Glutathione 0.10-0.5 11 P-hydroxyanisole 0.05-0.12 12 Potassium azeloyl diglycinate 0.090 13 Phytic acid 0.01-0.03 14 Peg-40 hydrogenated castor oil 0.30-0.60 15 Parfum q.b 16 Tocotrienols 0.01-0.05 17 Potassium undecylenoyl hydrolyzed wheat protein 0.050-1.0 18 Zinc coceth sulfate 0.050-0.1 19 Polyquaternium-16 0.020 20 Phenylalanine 0.2-0.6 21 Khellin 0.2-0.5 22 Water q.s to 100 ml - With the aim of better understanding the advantages of the invention, the following describes a clinical study carried out on healthy volunteers.
- An assessment was made of the effectiveness of a topical treatment for reducing the amount of white hair due to canities of two compositions in accordance with the invention, i.e.
- 1) hair mask formulated with liposomes
- 2) shampoo formulated with liposomes
- A double-blind clinical study was carried out using a mask 1-A in accordance with the invention comprising 1.5% w/v khellin in combination with phenylalanine, ornithine, copper gluconate and excipients suitable for topical application to hair, compared with the use of a placebo formulation 1-B, i.e. a similar mask base for hair but without the active principle.
- 50 volunteers, comprising 40 women and 10 men between 35 and 55 years of age, and healthy according to specific inclusion and exclusion criteria, including the exclusion of immunological pathologies and of systemic drug consumption were treated as follows.
- 1-A and 1-B were applied three times a week for eight weeks to each subject. At the end of the treatment, each subject was evaluated by:
- dermatological examination
- macro photograph (digital)
- epiluminescence (Molemax II)
- Reflectance Confocal Microscopy (RCM) using a Lucid confocal microscope.
- In 65% of the subjects treated with mask 1-A a 20-30% reduction in grey/white hair was found compared with a 2% reduction in grey/white hair in subjects treated with mask 1-B, with reduction of up to a maximum of 5%, p = 0.05.
- Additionally, of those treated with mask 1-A, an increase in the anagen phase of the hair growth cycle (compared to the baseline) as well as an increase in the hair shaft diameter were found in subjects affected by androgenetic alopecia.
- After having completed the assessment on the treatment with mask 1), the subjects in active group A used a gentle shampoo 2-A containing 1% khellin and formulated with liposomes, to be used twice weekly for four weeks.
- The subjects in non-active group B used a normal gentle shampoo 2-B as a comparison, i.e. without active principles.
- At the end of the four weeks, the assessments were repeated on all subjects.
- in group A it was found that the results obtained with mask 1-A application were maintained.
- in group B with free shampoo 2-B a slight increase in grey hair was noted, but was not statistically significant compared to the baseline of the non-active group. In conclusion, application of mask 1-A with the active principle of the invention has demonstrated a capacity to increase the number of repigmented hairs even though repigmentation of the whole head of hair was not observed.
- Application of shampoo 2-A was shown to be effective in maintaining the action of mask 1-A treatment.
- No systemic or localized side effects were noted on use of the products at the end of the reported study.
- The composition of the invention is mainly indicated for anti-ageing cosmetic use, for preventing and treating canities and hence ageing of the hair.
- It is particularly indicated for the treatment of greying hair and hair in the initial stages of canities for reducing its progression.
- Following topical application of the composition of the invention to hair, an increase in the anagen phase of the hair growth cycle (compared to the baseline) as well as an increase in hair shaft diameter in subjects affected by androgenetic alopecia was generally also apparent.
- For this reason, the composition of the invention is particularly indicated for the treatment of canities associated with androgenetic alopecia.
Claims (7)
- Use of khellin as a cosmetic for reducing the amount of grey or white hair due to canities.
- Use of khellin for reducing the amount of grey or white hair due to canities, while at the same time producing an increase in the anagen phase and hair shaft diameter in subjects affected by androgenetic alopecia.
- Use according to the preceding claims wherein khellin is formulated in a composition comprising excipients suitable for topical use on hair.
- Use according to the preceding claims wherein khellin is used in combination with one or more active compounds chosen from: phenylalanine, ornithine, catechin, quercetin, copper salts.
- Use according to the preceding claims wherein khellin is prepared in the form of a mask for hair treatment, or shampoo, or lotion, or conditioner, or mousse.
- Use according to claim 5 wherein the said form contains liposomes.
- Use according to the preceding claims wherein khellin is prepared in a composition in a quantity from 0.2 to 1.8% w/v.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08760661.2A EP2167026B1 (en) | 2007-06-11 | 2008-06-06 | Cosmetic composition for treatment of canities |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07425366A EP2005942A1 (en) | 2007-06-11 | 2007-06-11 | Cosmetic composition for treatment of canities |
EP08760661.2A EP2167026B1 (en) | 2007-06-11 | 2008-06-06 | Cosmetic composition for treatment of canities |
PCT/EP2008/057091 WO2008151994A1 (en) | 2007-06-11 | 2008-06-06 | Cosmetic composition for treatment of canities |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2167026A1 EP2167026A1 (en) | 2010-03-31 |
EP2167026B1 true EP2167026B1 (en) | 2015-12-09 |
Family
ID=38738811
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07425366A Withdrawn EP2005942A1 (en) | 2007-06-11 | 2007-06-11 | Cosmetic composition for treatment of canities |
EP08760661.2A Active EP2167026B1 (en) | 2007-06-11 | 2008-06-06 | Cosmetic composition for treatment of canities |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07425366A Withdrawn EP2005942A1 (en) | 2007-06-11 | 2007-06-11 | Cosmetic composition for treatment of canities |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP2005942A1 (en) |
WO (1) | WO2008151994A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2022478A1 (en) * | 2007-08-07 | 2009-02-11 | KPSS-Kao Professional Salon Services GmbH | Conditioning composition for hair |
DE102009044974A1 (en) * | 2009-07-23 | 2011-01-27 | Henkel Ag & Co. Kgaa | Use of dihydroquercetin and at least one amino acid to positively influence the natural pigmentation process |
FR2980691B1 (en) | 2011-09-30 | 2014-03-14 | Galderma Sa | WASHING COMPOSITION |
DE102011086636A1 (en) * | 2011-11-18 | 2013-05-23 | Henkel Ag & Co. Kgaa | Hair care products containing amino acids and cationic silicones |
WO2013179098A1 (en) * | 2012-06-01 | 2013-12-05 | Laboratori Farmaceutici Krymi S.P.A. | Association of potassium caproyl tyrosine, l-phenylalanine and taurine and use thereof to prevent and slow down white hair |
PL2919747T3 (en) | 2012-11-13 | 2019-03-29 | Galderma S.A. | Bpo wash gel composition |
WO2014076136A1 (en) | 2012-11-13 | 2014-05-22 | Galderma S.A. | Bpo wash emulsion composition |
FR3022778A1 (en) * | 2014-06-30 | 2016-01-01 | Oreal | USE OF A COMBINATION OF ORNITHINE AND CITRIC ACID TO LIMIT HAIR LOSS |
WO2018225482A1 (en) * | 2017-06-07 | 2018-12-13 | 花王株式会社 | Ammonia metabolism promoter |
IT201700080737A1 (en) * | 2017-07-17 | 2019-01-17 | Marilena Cammarota | Topical liposphere preparation to induce the repigmentation of skin areas affected by vitiligo. |
FR3132842A1 (en) * | 2022-02-21 | 2023-08-25 | L'oreal | compositions and methods for treating keratinous materials |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU85688A1 (en) * | 1984-12-18 | 1986-07-17 | Oreal | COSMETIC ACCELERATING TANNING BASED ON FUROCHROMONES |
IT1269634B (en) * | 1994-05-06 | 1997-04-08 | Indena Spa | TOPICAL MEDICATION WITH CICATRIZING ACTIVITY |
IT1278997B1 (en) * | 1994-07-19 | 1997-12-02 | Indena Spa | COMBINATIONS OF VASOACTIVE SUBSTANCES WITH FATTY ACIDS TO FIGHT HAIR LOSS |
FR2782920B1 (en) * | 1998-09-07 | 2000-10-06 | Oreal | USE OF AT LEAST ONE ROSACEA EXTRACT OF THE GENUS SANGUISORBA OFFICINALIS TO PROMOTE PIGMENTATION OF THE SKIN AND / OR HAIR |
DE19853425A1 (en) * | 1998-11-19 | 2000-05-25 | Martin Roecken | Topical composition containing khellin or its derivatives, useful for phototherapy of psoriasis and eczema, has low mitogenic potential |
DE10150445A1 (en) * | 2001-10-12 | 2003-04-17 | Beiersdorf Ag | Use of purine or pyrimidine compounds without oxidants in intensifying natural hair colors or in stimulating melanogenesis in human hair, e.g. in masking gray hair |
WO2003039596A1 (en) * | 2001-11-09 | 2003-05-15 | Qlt Inc. | Photodynamic therapy for the treatment of hair loss |
-
2007
- 2007-06-11 EP EP07425366A patent/EP2005942A1/en not_active Withdrawn
-
2008
- 2008-06-06 EP EP08760661.2A patent/EP2167026B1/en active Active
- 2008-06-06 WO PCT/EP2008/057091 patent/WO2008151994A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2005942A1 (en) | 2008-12-24 |
EP2167026A1 (en) | 2010-03-31 |
WO2008151994A1 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2167026B1 (en) | Cosmetic composition for treatment of canities | |
ES2398478T5 (en) | Stable soluble salts of phenylbenzimidazolsulfonic acid from pH 6.0 to less than 6.8 | |
US20060013845A1 (en) | Oxygenated personal care products | |
JP2011516524A (en) | Novel compositions and uses thereof | |
KR101516074B1 (en) | Compositions comprising Polydatin and Tranexamic acid for whitening | |
BR112021015309A2 (en) | ANTIMICROBIAL ACTIVITY OF FATTY ACID ESTERS AND COMBINATIONS THEREOF | |
US20240197605A1 (en) | Composition for Treating Hair, Scalp and Skin | |
US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
US10363207B2 (en) | All-in-one skin-brightening formulations | |
KR20160143793A (en) | Compositions and methods for reducing oxidative stress | |
KR101511252B1 (en) | Compositions comprising Atractyloides japonica rhizome extract and Tranexamic acid for whitening | |
US9066880B2 (en) | Use of dihydrodehydrodiisoeugenol and preparations comprising dihydrodehydrodiisoeugenol | |
KR100738434B1 (en) | Cosmetic composition containing pyrrolidinyl diaminopyrimidine oxide | |
KR102246477B1 (en) | Methods of reducing signs of skin aging | |
JPH03112912A (en) | Cosmetic composition | |
EP2862852B1 (en) | Urea derivatives for the protection of stem cells | |
KR101493483B1 (en) | Hair and scalp protective composition for hair dyeing | |
ES2367134T3 (en) | USE OF AN OXIALQUILENATED SORBITAN ESTER AS A CALMING LEATHER CALMING AGENT. | |
KR100441059B1 (en) | Composition for improving conditions of scalp and hair | |
KR20160133007A (en) | Topical composition including a combination of extracts for reducing signs of skin aging | |
ES2631191B1 (en) | COMPOSITION FOR SOLAR PROTECTION AND REPAIR OF THE SKIN THROUGH PROTECTIVE COMPLEXES | |
JPH03178922A (en) | Dandruff-suppressing agent composition | |
WO2024056566A1 (en) | Use of thioethylamine composition for skin rejuvenation and improved synergistic effect when combined with an organic acid and/or azabenzene-4-carboxamide | |
EP3922236A1 (en) | Compositions for topical treatment of acquired melanosis of the skin | |
JP2024517403A (en) | Hair treatment compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20120704 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150624 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 764240 Country of ref document: AT Kind code of ref document: T Effective date: 20151215 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008041561 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20151209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160309 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 764240 Country of ref document: AT Kind code of ref document: T Effective date: 20151209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160310 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160409 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160411 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008041561 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
26N | No opposition filed |
Effective date: 20160912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602008041561 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20160606 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20170228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170103 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160630 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160630 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160606 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160630 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151209 |